35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ADVANCES FOR SCIENCE AND PATIENTS RENEWS FOR ANOTHER THREE YEARS BETWEEN LA JOLLA INSTITUTE FOR IMMUNOLOGY AND KYOWA KIRIN
Kyowa Kirin (TSE: 4151) and La Jolla Institute for Immunology (LJI) have renewed their 35-year research partnership for another three years. The collaboration, which began in 1988, combines LJI's academic expertise with Kyowa Kirin's drug development capabilities.
The partnership has led to significant discoveries in immunology and supported first-in-class therapies for rare diseases. Notable developments include an immunotherapy for moderate to severe atopic dermatitis currently in Phase III clinical trials. Kyowa Kirin currently markets three therapies in North America and over 50 products worldwide in areas including hematology-oncology and rare bone disease.
The renewed agreement provides LJI with research funding, faculty hiring support, and project-specific research funds. The partnership's new focus will be on developing cell and gene therapies for diseases with or no treatment options, with preliminary data expected in 2025 for various conditions including ulcerative colitis, acute respiratory distress, and atopic dermatitis.
Kyowa Kirin (TSE: 4151) e l'Istituto La Jolla per l'Immunologia (LJI) hanno rinnovato la loro partnership di ricerca trentacinquennale per altri tre anni. La collaborazione, iniziata nel 1988, unisce l'expertise accademica del LJI con le capacità di sviluppo farmaceutico di Kyowa Kirin.
Questa partnership ha portato a scoperte significative in immunologia e ha supportato terapie di prima classe per malattie rare. Tra i progressi notevoli c'è un'immunoterapia per dermatite atopica da moderata a grave attualmente in fase III di sperimentazione clinica. Kyowa Kirin attualmente commercializza tre terapie in Nord America e oltre 50 prodotti in tutto il mondo in aree che includono ematologia-oncologia e malattie ossee rare.
L'accordo rinnovato fornisce al LJI finanziamenti per la ricerca, supporto per l'assunzione di docenti e fondi specifici per progetti di ricerca. Il nuovo focus della partnership sarà lo sviluppo di terapie cellulari e geniche per malattie senza opzioni di trattamento, con dati preliminari attesi nel 2025 per varie condizioni tra cui colite ulcerosa, distress respiratorio acuto e dermatite atopica.
Kyowa Kirin (TSE: 4151) y el Instituto La Jolla de Inmunología (LJI) han renovado su asociación de investigación de 35 años por otros tres años. La colaboración, que comenzó en 1988, combina la experiencia académica del LJI con las capacidades de desarrollo de fármacos de Kyowa Kirin.
La asociación ha llevado a descubrimientos significativos en inmunología y ha respaldado terapias de primera clase para enfermedades raras. Entre los desarrollos notables se encuentra una inmunoterapia para dermatitis atópica moderada a grave que actualmente se encuentra en ensayos clínicos de fase III. Kyowa Kirin comercializa actualmente tres terapias en América del Norte y más de 50 productos en todo el mundo en áreas que incluyen hematología-oncología y enfermedades óseas raras.
El acuerdo renovado proporciona al LJI financiamiento para investigación, apoyo para la contratación de profesores y fondos de investigación específicos para proyectos. El nuevo enfoque de la asociación se centrará en el desarrollo de terapias celulares y génicas para enfermedades sin opciones de tratamiento, con datos preliminares esperados en 2025 para diversas condiciones, incluida la colitis ulcerosa, el distress respiratorio agudo y la dermatitis atópica.
교와 키린 (TSE: 4151)과 라홀라 면역학 연구소 (LJI)는 35년 간의 연구 파트너십을 3년 더 연장했습니다. 1988년에 시작된 이 협력은 LJI의 학문적 전문성과 교와 키린의 약물 개발 능력을 결합합니다.
이 파트너십은 면역학에서 중요한 발견을 이끌어냈으며, 희귀 질환에 대한 최초의 치료법을 지원했습니다. 주목할 만한 발전 중 하나는 현재 3상 임상 시험 중인 중등도에서 중증 아토피 피부염에 대한 면역요법입니다. 교와 키린은 현재 북미에서 3가지 치료제를 판매하고 있으며, 혈액종양학 및 희귀 뼈 질환을 포함한 전 세계 50개 이상의 제품을 보유하고 있습니다.
갱신된 계약은 LJI에 연구 자금, 교수 채용 지원 및 특정 프로젝트 연구 자금을 제공합니다. 파트너십의 새로운 초점은 치료 옵션이 없거나 없는 질병에 대한 세포 및 유전자 치료법 개발에 있을 것이며, 2025년에는 궤양성 대장염, 급성 호흡 곤란 및 아토피 피부염을 포함한 다양한 질환에 대한 초기 데이터가 기대됩니다.
Kyowa Kirin (TSE: 4151) et l'Institut La Jolla pour l'immunologie (LJI) ont renouvelé leur partenariat de recherche de 35 ans pour trois années supplémentaires. La collaboration, qui a débuté en 1988, combine l'expertise académique du LJI avec les capacités de développement de médicaments de Kyowa Kirin.
Ce partenariat a conduit à des découvertes significatives en immunologie et a soutenu des thérapies de première classe pour des maladies rares. Parmi les développements notables, on trouve une immunothérapie pour la dermatite atopique modérée à sévère actuellement en essais cliniques de phase III. Kyowa Kirin commercialise actuellement trois thérapies en Amérique du Nord et plus de 50 produits dans le monde dans des domaines tels que l'hématologie-oncologie et les maladies osseuses rares.
Le nouvel accord fournit au LJI un financement pour la recherche, un soutien pour le recrutement de professeurs et des fonds de recherche spécifiques à des projets. Le nouveau focus du partenariat sera sur le développement de thérapies cellulaires et géniques pour des maladies sans options de traitement, avec des données préliminaires attendues en 2025 pour diverses conditions, y compris la colite ulcéreuse, le syndrome de détresse respiratoire aiguë et la dermatite atopique.
Kyowa Kirin (TSE: 4151) und das La Jolla Institute for Immunology (LJI) haben ihre 35-jährige Forschungskooperation um weitere drei Jahre verlängert. Die Zusammenarbeit, die 1988 begann, verbindet die akademische Expertise des LJI mit den Arzneimittelentwicklungskapazitäten von Kyowa Kirin.
Die Partnerschaft hat zu bedeutenden Entdeckungen in der Immunologie geführt und erstklassige Therapien für seltene Krankheiten unterstützt. Zu den bemerkenswerten Entwicklungen gehört eine Immuntherapie für mäßige bis schwere atopische Dermatitis, die sich derzeit in Phase-III-Studien befindet. Kyowa Kirin vertreibt derzeit drei Therapien in Nordamerika und über 50 Produkte weltweit in Bereichen wie Hämatologie-Onkologie und seltene Knochenerkrankungen.
Die erneuerte Vereinbarung stellt dem LJI Forschungsfinanzierung, Unterstützung bei der Einstellung von Fakultätsmitgliedern und projektbezogene Forschungsfonds zur Verfügung. Der neue Fokus der Partnerschaft wird auf der Entwicklung von zell- und gentherapeutischen Verfahren für Krankheiten ohne oder mit begrenzten Behandlungsmöglichkeiten liegen, wobei erste Daten für 2025 für verschiedene Erkrankungen wie Colitis ulcerosa, akute Atemnot und atopische Dermatitis erwartet werden.
- Renewal of successful 35-year research partnership secures continued drug development pipeline
- Multiple drug candidates in late-stage clinical trials with data expected in 2025
- Strong market presence with 3 therapies in North America and 50+ products worldwide
- Strategic expansion into cell and gene therapy development
- None.
-Agreement extends one of the world's most enduring alliances for drug discovery-
-Landmark discoveries from partnership have led to novel drug candidates, including an immunotherapy for moderate to severe atopic dermatitis currently in Phase III clinical trials-
- New focus on cell and gene therapies to accelerate novel treatments for patients with unmet medical needs -
LA JOLLA, Calif. and
The three-year agreement marks the latest milestone in one of the world's most enduring and prolific industry-academic collaborations, conceived in 1988 by a Japanese immunologist and funded by then Kirin Brewery's emerging pharmaceutical business to advance scientific exploration and immunologic research.
Today, LJI ranks among the world's top five immunology institutions, whose renowned faculty have transformed basic understanding of human immunity and paved the way for important clinical advances. Simultaneously, Kyowa Kirin has evolved into a leading global specialty pharmaceutical company that develops novel therapies for patients with rare and debilitating diseases. The company markets three therapies in
Together, the two organizations have created a unique alliance that blends the academic prowess of LJI with the drug development and commercialization expertise of Kyowa Kirin. Working side by side under one roof, scientists from LJI and Kyowa Kirin's
LJI scientists have made pioneering discoveries that harness the immune system against cancer, reveal key differences between the immune systems of men and women, and provide new opportunities to protect against emerging and infectious diseases.
"The unique and vibrant culture we've established over the past 35 years, coupled with the continuous research funding from Kyowa Kirin, has enabled our teams to make pioneering scientific contributions that have dramatically increased our understanding of human immunology," said LJI Professor, President & CEO Erica Ollmann Saphire, Ph.D., MBA. "Further, our proximity and open access to one another's respective scientific expertise, technical capabilities, and LJI's core facilities have fueled the identification and validation of target molecules as well as numerous candidate compounds adding life-changing value to the research we do."
Kyowa Kirin's research team has advanced several of these compounds into clinical trials for a range of conditions, including ulcerative colitis, acute respiratory distress, atopic dermatitis, with preliminary data anticipated in 2025.
"We're excited about our future with LJI and the opportunities it affords to shape a healthier future for patients with unmet medical needs," said Yoshifumi Torii, Ph.D., Executive Officer, Senior Vice President, Head of Global Research at Kyowa Kirin. "Pairing the best basic scientists and translational medicine researchers at the table from the beginning creates a more entrepreneurial way of thinking about drug discovery and development that promotes innovation and accelerates timelines on behalf of patients."
The renewed research agreement provides LJI with multiple types of support, including research funding, faculty hiring support, and project-specific research funds relating to Kyowa Kirin's therapeutic scope. Joint research will prioritize cell and gene therapies designed to treat diseases with limited or no treatment options. This focus aligns with Kyowa Kirin's commitment to addressing some of the world's most challenging and unmet medical needs.
About Kyowa Kirin
Kyowa Kirin aims to discover novel medicines and treatments with life-changing value. As a
About La Jolla Institute for Immunology
The La Jolla Institute for Immunology is dedicated to understanding the intricacies and power of the immune system so that we may apply that knowledge to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading toward its goal: life without disease. Visit lji.org for more information.
Media Contacts: Gina Kirchweger
gina@lji.org
848.357.7481
This news release was issued on behalf of Newswise™. For more information, visit http://www.newswise.com.
View original content:SOURCE La Jolla Institute for Immunology
FAQ
What are the key terms of Kyowa Kirin's (KYKOY) renewed partnership with La Jolla Institute?
How many products does Kyowa Kirin (KYKOY) currently market globally?
What clinical trials are expected to report data from Kyowa Kirin (KYKOY) in 2025?
What is the current status of Kyowa Kirin's (KYKOY) atopic dermatitis treatment?
